Study summary

Finerenone slowed kidney function loss in glomerular diseases including FSGS

Finerenone in glomerular diseases (FIND-CKD subgroup) · 903 people, phase 3 subgroup analysis · Published July 2026, JAMA

42%reduction in albuminuria at 12 months

What was tested

Finerenone, a nonsteroidal mineralocorticoid receptor blocker pill, against placebo, in a prespecified analysis of people with glomerular diseases (215 with FSGS) within a larger kidney trial.

What they found

What it means

Supports adding finerenone to kidney-protecting treatment, though it was an exploratory analysis.

JAMA, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.